Goldman Sachs
LKFT

Goldman Sachs’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Goldman Sachs’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.36M Buy
45,371
+34,227
+307% +$1.13M ﹤0.01% 4867
2025
Q4 		$364K Sell
11,144
-54,997
-83% -$1.78M ﹤0.01% 5773
2025
Q3 		$2.29M Buy
66,141
+9,410
+17% +$301K ﹤0.01% 4357
2025
Q2 		$1.59M Buy
+56,731
New +$1.52M ﹤0.01% 4356
2025
Q1 		– Sell
-24,731
Closed -$680K – 6197
2024
Q4 		$680K Sell
24,731
-27,287
-52% -$761K ﹤0.01% 5063
2024
Q3 		$1.5M Sell
52,018
-27,817
-35% -$757K ﹤0.01% 4376
2024
Q2 		$1.98M Sell
79,835
-11,650
-13% -$331K ﹤0.01% 3931
2024
Q1 		$2.95M Sell
91,485
-27,600
-23% -$1.03M ﹤0.01% 3553
2023
Q4 		$4.84M Buy
119,085
+43,918
+58% +$1.62M ﹤0.01% 3187
2023
Q3 		$2.6M Buy
75,167
+48,958
+187% +$1.91M ﹤0.01% 3555
2023
Q2 		$1.07M Sell
26,209
-16,236
-38% -$662K ﹤0.01% 4302
2023
Q1 		$1.64M Sell
42,445
-21,124
-33% -$868K ﹤0.01% 4018
2022
Q4 		$2.82M Buy
63,569
+19,766
+45% +$832K ﹤0.01% 3657
2022
Q3 		$1.87M Buy
43,803
+23,970
+121% +$1.23M ﹤0.01% 4037
2022
Q2 		$1.11M Sell
19,833
-43,165
-69% -$2.56M ﹤0.01% 4533
2022
Q1 		$3.91M Sell
62,998
-13,187
-17% -$807K ﹤0.01% 3584
2021
Q4 		$4.2M Buy
76,185
+13,100
+21% +$683K ﹤0.01% 3578
2021
Q3 		$3.32M Sell
63,085
-2,759
-4% -$164K ﹤0.01% 3724
2021
Q2 		$4.54M Sell
65,844
-194,243
-75% -$14.8M ﹤0.01% 3422
2021
Q1 		$20.1M Buy
260,087
+225,710
+657% +$20.8M 0.01% 1930
2020
Q4 		$3.4M Buy
34,377
+21,776
+173% +$2.66M ﹤0.01% 3309
2020
Q3 		$1.79M Sell
12,601
-8,490
-40% -$1.42M ﹤0.01% 3644
2020
Q2 		$4.16M Sell
21,091
-4,955
-19% -$1.03M ﹤0.01% 2936
2020
Q1 		$5.1M Buy
26,046
+7,972
+44% +$1.72M ﹤0.01% 2622
2019
Q4 		$3.74M Buy
18,074
+5,436
+43% +$1M ﹤0.01% 3188
2019
Q3 		$1.93M Buy
12,638
+7,747
+158% +$1.27M ﹤0.01% 3557
2019
Q2 		$631K Sell
4,891
-3,881
-44% -$460K ﹤0.01% 4277
2019
Q1 		$1.03M Buy
8,772
+3,069
+54% +$309K ﹤0.01% 4029
2018
Q4 		$523K Buy
5,703
+537
+10% +$54.4K ﹤0.01% 4339
2018
Q3 		$581K Sell
5,166
-3,443
-40% -$364K ﹤0.01% 4349
2018
Q2 		$794K Sell
8,609
-2,101
-20% -$204K ﹤0.01% 4229
2018
Q1 		$1.07M Sell
10,710
-105,906
-91% -$11.4M ﹤0.01% 4008
2017
Q4 		$10.9M Sell
116,616
-4,520
-4% -$428K ﹤0.01% 2396
2017
Q3 		$12.3M Sell
121,136
-81,037
-40% -$7.08M ﹤0.01% 2383
2017
Q2 		$15.5M Buy
202,173
+1,235
+0.6% +$104K ﹤0.01% 2157
2017
Q1 		$17.3M Sell
200,938
-43,100
-18% -$3.1M ﹤0.01% 1988
2016
Q4 		$15.7M Sell
244,038
-45,300
-16% -$2.79M ﹤0.01% 2127
2016
Q3 		$18.7M Sell
289,338
-10,780
-4% -$608K 0.01% 1940
2016
Q2 		$16.6M Sell
300,118
-49,645
-14% -$2.5M 0.01% 1930
2016
Q1 		$14.6M Sell
349,763
-19,323
-5% -$897K ﹤0.01% 1945
2015
Q4 		$23.2M Buy
369,086
+35,712
+11% +$1.83M 0.01% 1657
2015
Q3 		$13.6M Buy
333,374
+163,792
+97% +$9.44M ﹤0.01% 2012
2015
Q2 		$8.73M Buy
+169,582
New +$9M ﹤0.01% 2450

Other funds holding LKFT

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
SBH
Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs's LKFT Position: Q1 2026 in Review

Goldman Sachs increased its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 307% in Q1 2026, buying an estimated $1.13M and bringing the position to 45,371 shares worth $1.36M. The position accounts for ﹤0.01% of the portfolio, ranked #4867.

Goldman Sachs first reported a position in LKFT in Q2 2015 and has held it in 43 quarters since. The position peaked at $23.2M in Q4 2015. 90 funds tracked by Wall St. Rank hold LKFT as of Q1 2026.

  • Goldman Sachs held 45,371 shares of Lakefront Biotherapeutics American Depositary Shares worth $1.36M as of Q1 2026.
  • Goldman Sachs bought 34,227 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2026, an estimated $1.13M.
  • Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4867 holding.
  • Goldman Sachs first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q2 2015 and has held it in 43 quarters since.
  • Goldman Sachs's Lakefront Biotherapeutics American Depositary Shares position peaked at $23.2M in Q4 2015.
  • 90 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.